Establishment and application of key technologies and systems for improving health care quality of cerebrovascular diseases——The Second Prize of 2020 National Science and Technology Progress

doi:10.3969/j.issn.1006-7795.2022.01.002

Abstract

Abstract: Cerebrovascular disease is the first cause of adult disability and death at present in our country. The team led by Professor Wang Yongjun has developed a set of cerebrovascular disease treatment technology based on image feature, biological markers, and new gene indicators to reduce the recurrence rates, morbidity and mortality during 18 years, which has reduced the recurrence rate of cerebrovascular disease by 37%-73% relatively. Furthermore, the team has established an improvement and transformation technology system for medical quality, with the standardized application of precision treatment technology as the core. The one-year recurrence rate of cerebrovascular disease was reduced by 28%, and the disability rate by 26%. It means that they have explored an effective way of medical transformational technology into clinical practice. In addition, the team has integrated organizational management mode, hierarchical quality control framework and information data platform, real-time monitoring, and feedback of medical service quality into a medical quality improvement system of cerebrovascular disease, which covers 2 497 hospitals across the country. It effectively promotes the transformation and application of appropriate diagnosis and treatment technologies into clinical practice. The standardized implementation rate of cerebrovascular disease medical quality index in China was increased by 21%. The accumulative conversion funds were 105 million Yuan.

Key words: cerebrovascular disease, health care quality, precision medicine, improvement

CLC Number:

R743

Li Zixiao, Zhao Xingquan, Wang Yongjun. Establishment and application of key technologies and systems for improving health care quality of cerebrovascular diseases——The Second Prize of 2020 National Science and Technology Progress[J]. Journal of Capital Medical University, 2022, 43(1): 6-12.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.01.002

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I1/6

References

[1] Wang Y L, Johnston S C, Wang Y J. Clopidogrel with aspirin in minor stroke or transient ischemic attack[J]. N Engl J Med, 2013, 369(14): 1376-1377.
[2] Kernan W N, Ovbiagele B, Black H R, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart association/American stroke association[J]. Stroke, 2014, 45(7): 2160-2236.
[3] Pan Y S, Meng X, Jing J, et al. Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA[J]. Neurology, 2017, 88(11): 1081-1088.
[4] Jing J, Meng X, Zhao X Q, et al. Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial[J]. JAMA Neurol, 2018, 75(6): 711-719.
[5] Zhu B H, Pan Y S, Jing J, et al. Neutrophil counts, neutrophil ratio, and new stroke in minor ischemic stroke or TIA[J]. Neurology, 2018, 90(21): e1870-e1878.
[6] Li J J, Wang A X, Zhao X Q, et al. High-sensitive C-reactive protein and dual antiplatelet in intracranial arterial stenosis[J]. Neurology, 2018, 90(6): e447-e454.
[7] Pan Y S, Chen W Q, Wang Y L, et al. Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack: secondary analysis of a randomized clinical trial[J]. JAMA Neurol, 2019, 76(5): 552-560.
[8] George B P, Falcone G J. One step closer to precision medicine strategies based on genetic information: ABCB1 polymorphisms in the CHANCE trial[J]. JAMA Neurol, 2019, 76(5): 523-525.
[9] Wang Y L, Zhao X Q, Lin J X, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack[J]. JAMA, 2016, 316(1): 70-78.
[10] Pan Y S, Chen W Q, Xu Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis[J]. Circulation, 2017, 135(1): 21-33.
[11] Xu J, Wang A X, Wangqin R Q, et al. Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile[J]. Ann Neurol, 2019, 86(3):419-426.
[12] Algra A, Wermer M J H. Stroke in 2016: stroke is treatable, but prevention is the key[J]. Nat Rev Neurol, 2017, 13(2): 78-79.
[13] Simon T, Danchin N. Clinical impact of pharmacogenomics of clopidogrel in stroke[J]. Circulation, 2017, 135(1): 34-37.
[14] Wang Y L, Chen W Q, Lin Y, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial[J]. BMJ, 2019, 365: 12211.
[15] Warner J J, Harrington R A, Sacco R L, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke[J]. Stroke, 2019, 50(12): 3331-3332.
[16] Wang Y J, Johnston S C, Bath P M, et al. Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack[J]. BMJ, 2019, 364: 1895.
[17] Yang X M, Li Z X, Zhao X Q, et al. Use of warfarin at discharge among acute ischemic stroke patients with nonvalvular atrial fibrillation in China[J]. Stroke, 2016, 47(2): 464-470.
[18] Wang Y L, Liao X L, Zhao X Q, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese national stroke registry (CNSR)[J]. Stroke, 2011, 42(6): 1658-1664.
[19] Wang Y L, Li Z X, Zhao X Q, et al. Evidence-based performance measures and outcomes in patients with acute ischemic stroke[J]. Circ Cardiovasc Qual Outcomes, 2018, 11(12): e001968.
[20] Wang Y L, Li Z X, Zhao X Q, et al. Effect of a multifaceted quality improvement intervention on hospital personnel adherence to performance measures in patients with acute ischemic stroke in China: a randomized clinical trial[J]. JAMA, 2018, 320(3): 245-254.
[21] Hill M D, Kamal N, Jeerakathil T. Bridging the Evidence-to-Practice gap in stroke care[J]. JAMA, 2018, 320(3): 236-237.
[22] Li Z X, Jiang Y, Li H, et al. China's response to the rising stroke burden[J]. BMJ, 2019, 364: l879.
[23] Ma R H, Wang Y J, Qu H, et al. Assessment of the early effectiveness of a stroke unit in comparison to the general ward[J]. Chin Med J, 2004, 117(6): 852-855.
[24] Tuttolomondo A, Pinto A. C-reactive protein and efficacy of antiplatelet therapy in (intracranial) atherosclerosis[J]. Neurology, 2018, 90(6): 253-254.